PGT-A is designed to enhance embryo selection by detecting chromosomal abnormalities that may hinder the implantation process or lead to miscarriage and genetic disorders. It is estimated that more than 50% of embryos created during IVF cycles have some form of chromosomal abnormality, and this rate is expected to be even higher in women of advanced maternal age (over 35 years old). By screening for these abnormalities, PGT-A helps identify the healthiest embryos for transfer, thus optimizing the chances of achieving a successful pregnancy per embryo transfer.
PGT-A and Its Impact on Pregnancy and Live Birth Rates
Pregnancy Rate per Embryo Transfer: PGT-A can significantly increase the pregnancy rate per embryo transfer by allowing clinicians to select euploid embryos (those with the correct number of chromosomes) for transfer. By focusing on genetically normal embryos, PGT-A enhances the likelihood that the transferred embryo will successfully implant and lead to a pregnancy. This means that for each embryo transfer, the chances of achieving a pregnancy are higher when PGT-A is utilized if indicated.
Cumulative Live Birth Rates: While PGT-A improves the pregnancy rate per embryo transfer, it does not necessarily increase cumulative live birth rates over multiple IVF cycles. Cumulative live birth rates refer to the overall probability of achieving at least one live birth after a series of IVF attempts, considering all embryos transferred across those cycles. Although selecting euploid embryos can enhance the success of individual transfers, the total number of embryos available and the overall success of multiple IVF cycles may not see a significant increase due to factors such as the availability of viable embryos and the potential for miscarriages in subsequent cycles.
Detection vs. Correction of Genetic Abnormalities: PGT-A is designed to detect chromosomal abnormalities in embryos, allowing for informed decisions about which embryos to transfer. However, it cannot correct any existing genetic abnormalities. If an embryo is found to have chromosomal abnormalities through PGT-A, it can be excluded from transfer, but there is no current technology available that can correct these abnormalities within embryos. Therefore, PGT-A serves as a screening tool rather than a therapeutic intervention for genetic issues.
In summary, PGT-A enhances the likelihood of pregnancy for each embryo transferred but does not improve the overall cumulative live birth rates across multiple cycles. Additionally, while it can identify chromosomal abnormalities in embryos, it cannot correct these abnormalities.
Yes, Preimplantation genetic testing for aneuploidies (PGT-A) has been proposed as a tool that could potentially increase the success rates of in vitro fertilization (IVF). PGT-A allows the identification of embryos with an abnormal number of chromosomes (aneuploidies) before they are transferred to the uterus. The goal is to improve implantation rates and reduce the risk of miscarriage, especially in cases where chromosomal abnormalities are more likely to occur.
When reviewing the scientific evidence available, the potential benefits of PGT-A in IVF can be summarized as follows:
There are several important factors to consider when evaluating PGT-A.
While some studies have demonstrated improved implantation rates and reduced miscarriage rates with PGT-A, other research has not shown a significant improvement in live birth rates, particularly in younger women with a good ovarian reserve.
In conclusion, PGT-A may improve the success rates of IVF in certain groups, especially those at higher risk for chromosomal abnormalities, such as women over 35 or those with recurrent IVF failures. However, it is not a guaranteed solution for all patients and should be considered based on individual circumstances.
This is a very debatable area for the past 30 years. The debate is upon the use and whether this add on to the IVF procedure really helps increase the IVF success rate and whether the embryo genetic diagnosis is one 100% accurate. What we know so far for the meta analysis and research, is that it is not a 100% percent accurate screening test, it has a percentage of false positive and negative results so it has a percentage of misdiagnosis. It also has been shown that it does not increase the cumulative live birth rates. So it might increase the chances of having a baby earlier and not having a miscarriage during your IVF process. However it does not increase the cumulative birth rate.
The diagnosis doesn’t increase the quality of the genetic material. It only suggests a recommendation to the clinical staff not to transfer the embryos with no possibility of developing into a normal pregnancy.
Removing those embryos from the reproductive circuit that are chromosomally abnormal reduces the time to achieve pregnancy for a couple. We can help them make a final diagnosis for which maybe if the couple continues to use their own gametes, they will not get a full-term pregnancy.
The diagnosis could be useful for the couple. Sometimes couples that have failed many times want to have an answer. The answer is most possibly positive with the pregnancy or negative answers saying this gamete will never develop into a pregnancy. So other routes are to be found to look for a full-term pregnancy; it could be a sperm donation or oocyte donation, adoption or stopping looking for a baby.
Pre-Implantation Genetic Screening (or testing) is a procedure that checks whether an embryo is euploid – that is, whether it has the correct number of chromosomes. The results of this test tell us which embryos are the best candidates for a transfer. Only transferring embryos that we know are chromosomally normal gives us higher chances of success.
On its own, PGS does not improve pregnancy chances during a cycle, as pregnancy depends on more factors than just embryo quality. However, pregnancy rates are higher, and the likelihood of miscarriage is lower when euploid embryos are transferred. Genetically imperfect embryos are one of the most common causes of pregnancy loss. The time to pregnancy also decreases through PGS testing, as we’re eliminating the possibility of transferring aneuploid embryos.
PGS is the old name for the technique now called PGT-A (Preimplantation Genetic Testing for Aneuploidies). It can increase IVF success rates, especially in patients with a history of failed treatments. It is not a way of improving embryo quality, however. All it allows us to do is to discard those embryos, which have chromosomal abnormalities – as a result, we only transfer healthy embryos. Because of this, we reduce the number of transfers, the chance of miscarriage, the time to pregnancy, and costs for IVF patients, while simultaneously increasing the chances of a healthy pregnancy.
We evaluate developing embryos by checking several parameters. The quality of the embryo is initially judged only by a morphological assessment, not a genetic one; only PGT, however, can give us the full picture of an embryo’s health.
There is an established link between a woman’s age and the ratio of aneuploid embryos eggs result in; this, in turn, leads to a decline in overall fertility. Even in egg donors, up to 35% of generated blastocysts could carry genetic defects. The reason for that is cell division – that is, in women of advanced maternal age, eggs are less likely to undergo correct division, leading to cells with an incorrect distribution of chromosomes. Embryos generated from oocytes of women in advanced maternal age are more likely to have chromosomal abnormalities, even if morphologically they look healthy; as such, the only way to detect truly healthy embryos is PGT.
IVF failure can also be caused by the male factor. Although problems with the male factor usually cause problems, such as fertilization failure or the arrest of embryo development, the sperm can also carry aneuploidies, structural chromosome abnormalities, meiotic defects, and others. The bottom line is PGT can increase IVF success rates by helping fertility specialists only transfer genetically normal embryos, which have a greater chance to result in a healthy pregnancy.
If you have two embryos – one that has been biopsied and is known to be genetically normal, and another, which has the same morphological quality (and we can tell it’s genetically normal even without a biopsy, due to the way it developed), then these two embryos have the same chance of implanting. Thus, the biopsy itself doesn’t increase the implantation chance, but it also doesn’t reduce it.
The important concept is whether the embryo looks normal when examined under a microscope; at the moment, we can’t tell whether it’s genetically normal simply by examining it visually. Women under 35 have a high chance of producing genetically normal embryos; that chance goes down with age. The probability of producing genetically abnormal embryos can also be increased with ovarian stimulation; that probability can also be profoundly affected by male factor infertility.
PGS identifies the genetically normal embryo; in that way, it has been shown to change three things: it can decrease the number of embryo transfers needed to create an ongoing pregnancy, decrease the time needed to establish a healthy pregnancy, and it can also reduce the risk of miscarriage.
To answer the question, does PGS increase the success rates in IVF, the answer is both yes and no. For an individual patient who requires IVF, PGS can decrease the time it takes to achieve pregnancy, even if the biopsy itself doesn’t increase the chances of the embryo implanting compared to one that hasn’t been biopsied.
